Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 30, Issue 1, 2010, Pages 66-71

  Cioni, Antonio ^a   Sordini, Caterina ^a   Cavallini, Ivo ^a   Bigazzi, Roberto ^a   Campese, Vito M ^b  

^a Spedali Riuniti Livorno   (Italy)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

End stage renal disease (ESRD); HOMA; Insulin resistance; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BICARBONATE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FUROSEMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PHOSPHATE BINDING AGENT; POTASSIUM; TELMISARTAN; TRIACYLGLYCEROL; VITAMIN D;

ARTICLE; BICARBONATE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEMODIALYSIS PATIENT; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FAILURE; MALE; PERITONEAL DIALYSIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; CROSS-OVER STUDIES; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; PERITONEAL DIALYSIS;

EID: 77957664474     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2008.00155     Document Type: Article

References (31)

1. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest 1981; 67:563-8.
2. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2000; 15:65-70.
3. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
4. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116:1813-22.
5. Castellino P, Luzi L, Giordano M, DeFronzo RA. Effect of insulin and amino acids on glucose and leucine metabolism in CAPD patients. J Am Soc Nephrol 1999; 10:1050-8.
6. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2):S37-41.
7. De Santo NG, Capodicasa G, Senatore R, Cicchetti T, Cirillo D, Damiano M, et al. Glucose utilization from dialysate in patients on continuous ambulatory peritoneal dialysis (CAPD). Int J Artif Organs 1979; 2:119-25.
8. Sowers JR. Hypertension, angiotensin II, and oxidative stress. N Engl J Med 2002; 346:1999-2001.
9. Higashiura K, Ura N, Miyazaki Y, Shimamoto K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999; 13(Suppl 1):S71-4.
10. Laakso M, Karjalainen L, Lempiainen-Kuosa P. Effects of losartan in insulin sensitivity in hypertensive subjects. Hypertension 1996; 28:392-6.
11. Kurtz TW, Pravenec M. Antidiabetic mechanisms of ACE inhibitors and AII receptor antagonists: beyond the reninangiotensin system. J Hypertens 2004; 22:2253-61.
12. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89:463-78.
13. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-modulating activity. Hypertension 2004; 43: 993-1002.
14. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4:6-13.
15. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects [Letter]. Diabetes Care 2005; 28:498.
16. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27:1015.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
18. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22: 818-82.
19. Podel J, Hodelin-Wetzel R, Saha DC, Burns G. Glucose absorption in acute peritoneal dialysis. J Ren Nutr 2000; 10: 93-7.
20. Bodnar DM, Busch S, Fuchs J, Piedmonte M, Schreiber M. Estimating glucose absorption in peritoneal dialysis using peritoneal equilibration tests. Adv Perit Dial 1993; 9:114-18.
21. Mistry CD, Gokal R, Peers E, and the Midas Study Group. A randomized multicenter clinical trial comparing isoosmolar icodextrin with hyperosmolar glucose solutions in CAPD. Kidney Int 1994; 46:496-503.
22. Prichard S. Major and minor risk factors for cardiovascular disease in peritoneal dialysis. Perit Dial Int 2000; 20(Suppl 2):S154-9.
23. Amici G, Orrasch M, Da Rin G, Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2001; 17:80-3.
24. Rodriguez-Carmona A, Perez Fontan M, Garcia Lopez E, Garcia Falcon T, Diaz Cambre H. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007; 27:260-6.
25. Canbakan M, Sahin GM. Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients. Ren Fail 2007; 29:289-93.
26. Mather K, Anderson TJ, Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res 2001; 38:415-22.
27. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-κB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008; 294:E345-E351.
28. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001; 38:884-90.
29. Shimabukuro M, Tanak H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007; 25:841-8.
30. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-23.
31. Berk BC, Haendeler J, Sottile J. Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest 2000; 105:1525-6.